Learn about emerging treatments for advanced leukemia. We’ve got it covered, from new FDA approvals to emerging approaches in stem-cell transplants, targeted therapy, immunotherapy, and more.

  • October 16, 2020 

    Acute Myeloid Leukemia (AML)—An OverviewBookmark

    George Lundberg, MD

    Overview from Medscape curated by Contributing Editor George Lundberg, MD, who notes:

    This 2020 encyclopedic update with treatment options for all stages of acute myeloid leukemia is comprehensive and clear. (Free registration required, written with a physician audience in mind.)

    .

  • October 8, 2020 

    Oral Azacitidine Wins FDA Approval for AMLBookmark

    George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    The U.S. Food and Drug Administration (FDA) has approved oral azacitidine (brand name Onureg) based on clinical trial results showing a 10-month improvement in overall survival for patients with acute myeloid leukemia who are ineligible for transplant.

    .

  • October 8, 2020 

    Raising the Bar for Myelofibrosis Therapy DevelopmentBookmark

    George Lundberg, MD

    Article from MedPage Today curated by Contributing Editor George Lundberg, MD, who notes: 

    Myelodysplastic syndrome (MDS) commonly occurs before a patient develops acute leukemia, and is largely unresponsive to therapy. Two new clinical trials are entering phase 3 and may offer some hope.

    .

  • August 15, 2020 

    NCCN Clinical Practice Guidelines in Oncology: 2020 UpdatesBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    The National Comprehensive Cancer Network (NCCN) recently made key updates to its clinical practice guidelines. This news story provides a summary of the updates.

    Go to full news story published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019 

    FDA Approves Acalabrutinib for CLL/SLL as Part of Project OrbisBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In an unusual collaboration between the U.S. Food and Drug Administration (FDA), Canada, and Australia, acalabrutinib (Calquence) has been approved as another first line therapy for chronic lymphatic leukemia/small cell lymphoma.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

    • Show More
Cancer Commons is truly unique at rapidly matching patients with advanced cancer with the best precision therapy or clinical trial.

E. David Crawford, MD
Cancer Commons Advisor

Some of the most promising new treatments for advanced leukemia are currently being tested in patients enrolled in clinical trials. We help you stay up to date on the latest results from these studies.

  • November 12, 2019 

    ADMIRAL: Gilteritinib vs Chemotherapy in Relapsed or Refractory FLT3-Mutated AMLBookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    A clinical trial showed substantial benefits of progression-free survival and overall survival for patients with a particular form of acute myeloid leukemia when treated by gilteritinib versus chemotherapy. However, the disease was still fatal.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

    • Show More
Now is the time to be very actively involved in your own care.

Tony Blau, MD
University of Washington

Cancer affects many aspects of life, whether you’re newly diagnosed, in the midst of treatment, or in follow-up care. Learn about ways to maintain quality of life, such as palliative care and managing side effects.

  • October 14, 2019 

    Pediatric Palliative Care: A Specialty Comes of Age

    Sarah Friebert, MD

    For a child with cancer, palliative care can provide much-needed relief from stress and symptoms—for the patient and their family alike. Palliative care is given alongside cancer treatment, and is not synonymous with “end-of-life” care. In fact, anyone with a serious illness can benefit from palliative care, no matter their long-term outlook. Because of its importance for children with cancer, we are honored to… Read more »

  • February 11, 2020 

    ‘Impressed With Impact’ of Ketamine in Cancer Palliative CareBookmark

    George Lundberg, MD

    Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

    Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.

    Go to full article published by Medscape.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • October 7, 2019 

    Emphasizing Oncogeriatrics

    With: Nicolò Matteo Luca Battisti, MD

    A Q&A with Nicolò Matteo Luca Battisti, MD, Medical Oncologist at The Royal Marsden NHS Foundation Trust, London, United Kingdom, and Chair of the Young Interest Group of the International Society of Geriatric Oncology (SIOG); nicolo.battisti@gmail.com Q: Everyone knows that the practice of pediatric oncology is very different from adult oncology. How does the growing field of oncogeriatrics differ from usual adult oncology? A:… Read more »

  • August 26, 2019 

    Long-Term Infection Risk in Kids With LeukemiaBookmark

    George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    Survivors of childhood leukemia are more susceptible to infections than are others, even many years later.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 3, 2018 

    Best Uses of Physical Medicine and Rehabilitation in Patients with Cancer

    With: Val Jones, MD

    A Q&A with Val Jones, MD, Medical Director of Admissions, Saint Luke’s Rehabilitation Institute, Spokane, WA Originally published February 1, 2017 Q: Your principal practice in Spokane, Washington is physical medicine and rehabilitation (PM&R). What do you find to be the best uses of PM&R in patients with cancer at your facility? A: Rehabilitation medicine is one of the best-kept secrets in healthcare. Although the… Read more »

  • September 14, 2018 

    Huge Progress in Palliative Care

    With: Diane E. Meier, MD, FACP

    A Q&A with Diane E. Meier, MD, FACP, Director, Center to Advance Palliative Care; Professor of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai; New York, NY; diane.meier@mssm.edu Originally published November 8, 2017 Q: You wrote in MedGenMed in 2007 that palliative care was the job of all hospitals. In October 2017 you were honored at the National Academy of Medicine for… Read more »

    • Show More

You’re not alone. Read how other patients and caregivers navigated diagnosis, treatment, and life with cancer. We hope their stories provide insights and hope for your own cancer journey.

More patient stories

Learn more about what’s new in advanced cancer research and treatment, including screening and statistics, using artificial intelligence to improve treatment, and other new horizons in cancer care.

  • April 7, 2021 

    Rankings of Most Common and Deadly Cancer Types Will Shift Over Next Two Decades

    In the next two decades, rankings of incidence and death across cancer types will undergo important changes in the U.S., according to new research led by Lola Rahib, PhD, Director of Scientific and Clinical Affairs at Cancer Commons, as well as the Pancreatic Cancer Action Network (PanCAN) in collaboration with The University of Texas MD Anderson Cancer Center. Published today in JAMA Network Open,… Read more »

  • March 29, 2021 

    Can Really Big Data Inform Precise Decisions for Individual Patients?

    With: Matvey B. Palchuk, MD, MS, FAMIA

    New technologies are transforming cancer research. By optimizing research protocols and leveraging data more efficiently and intelligently, these tools hold the promise to improve personalized cancer care. Here, our Curious Dr. George asks Matvey B. Palchuk, MD, MS, FAMIA, VP of Informatics at TriNetX, LLC, about the capabilities of his company’s platform. Curious Dr. George: Translational medicine has evolved to include personalized medicine and… Read more »

  • November 10, 2020 

    How to Learn About Cancer in a Classroom: Shaping Compassionate Doctors

    With: Marin Langlieb

    The patients and caregivers we serve here at Cancer Commons rely on their doctors to provide expert, compassionate care. Building the skills to give such care can begin early in a doctor’s education. Here, for a change of pace, our Curious Dr. George asks a future doctor about a unique experience that helped her learn how to connect with cancer patients. Marin Langlieb is… Read more »

  • September 9, 2020 

    Is Cancer the Best Way to Die?

    With: Richard Smith, CBE, FMedSci

    In 2014, the prestigious medical research journal The BMJ published a controversial piece called “Dying of cancer is the best death.” Here, our Curious Dr. George asks the author of that piece, Richard Smith, CBE, FMedSci, if and how his thoughts on death have since evolved. Dr. Smith was Editor of The BMJ from 1991 to 2004 and is currently Chair of the Lancet Commission… Read more »

  • August 21, 2020 

    The Power of Precision Medicine is Exemplified by Tempus

    With: Nike Beaubier, MDNamratha Sastry, PhD

    Tempus—a tech company & partner of Cancer Commons—empowers doctors to make data-driven decisions for their patients in real time. Learn how.

  • June 29, 2020 

    Cancer Screening Programs Influence Incidence and Causes of Cancer DeathsBookmark

    Lola Rahib, PhD

    Article from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.

    In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.

    Go to full article published by ASCO Daily News.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

    • Show More

The coronavirus pandemic presents unprecedented challenges to cancer patients. We can help you understand how COVID-19 might impact your treatment and other aspects of your cancer care.